Fabhalta (iptacopan) was approved by UK drugs regulator the MHRA last month, becoming an option for an estimated 220 out of ...

The March meeting of the EMA’s human medicines committee (CHMP) saw an approval recommendation for Novartis’ Fabhalta, on track to become the first oral monotherapy for rare disease paroxysmal ...

The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.

The announcement comes just one month after the FDA granted accelerated approval to Novartis’ Fabhalta (iptacopan) to reduce proteinuria in adults with IgAN at risk of rapid disease progression.

In a report released yesterday, Florent Cespedes from Bernstein maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Iptacopan (Fabhalta) is available on the NHS. It is a possible treatment for paroxysmal nocturnal haemoglobinuria in adults with haemolytic anaemia. Your healthcare professionals should give you clear ...

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.

Jefferies is more bullish than consensus estimates on Novartis’s longer-term growth trajectory due to optimism in the new launches of its Scemblix, Pluvicto & Fabhalta drugs, the analysts add.

Last month, pharma giant Novartis NVS also entered the IgAN market after the FDA granted accelerated approval to Fabhalta for reducing proteinuria in adults with primary IgAN at risk of rapid ...

Then the FDA in August handed Novartis’ complement inhibitor Fabhalta an accelerated approval. The Swiss pharma’s selective ETA receptor inhibitor, atrasentan, is also under FDA review.

The news comes as NICE marks its 1000th medicine evaluation since April 1999 when it formed. Of the appraisals, more than ...

A critical factor in Jefferies' downgrade is the anticipated delay in market optimism surrounding Novartis' new product launches, including Scemblix, Pluvicto, and Fabhalta. “However, it will take ...